A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status
S1933 will close to accrual, effective February 15, 2026, at 12:00pm Pacific Time.
